INVESTIGATION OF MODIFIED SORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA VIA MOLECULAR DOCKING. Frontier in Medical and Health Research, [S. l.], v. 4, n. 5, p. 567–585, 2026. Disponível em: https://fmhr.net/index.php/fmhr/article/view/2904.. Acesso em: 26 jul. 2026.